A detailed history of Rhumbline Advisers transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 72,461 shares of VYGR stock, worth $423,896. This represents 0.0% of its overall portfolio holdings.

Number of Shares
72,461
Previous 46,447 56.01%
Holding current value
$423,896
Previous $432,000 32.64%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$7.42 - $10.54 $193,023 - $274,187
26,014 Added 56.01%
72,461 $573,000
Q1 2024

May 09, 2024

BUY
$7.15 - $10.84 $26,533 - $40,227
3,711 Added 8.68%
46,447 $432,000
Q4 2023

Feb 08, 2024

SELL
$6.28 - $8.81 $1,909 - $2,678
-304 Reduced 0.71%
42,736 $360,000
Q3 2023

Nov 09, 2023

BUY
$7.55 - $11.25 $12,298 - $18,326
1,629 Added 3.93%
43,040 $333,000
Q2 2023

Aug 08, 2023

BUY
$6.94 - $13.99 $287,392 - $579,339
41,411 New
41,411 $474,000
Q2 2021

Aug 05, 2021

SELL
$3.94 - $5.44 $133,439 - $184,241
-33,868 Closed
0 $0
Q1 2021

May 06, 2021

SELL
$4.61 - $9.04 $5,993 - $11,751
-1,300 Reduced 3.7%
33,868 $160,000
Q4 2020

Feb 10, 2021

BUY
$7.15 - $12.28 $22,165 - $38,068
3,100 Added 9.67%
35,168 $251,000
Q3 2020

Nov 12, 2020

SELL
$10.01 - $13.75 $49,499 - $67,993
-4,945 Reduced 13.36%
32,068 $342,000
Q2 2020

Aug 13, 2020

BUY
$8.05 - $14.21 $27,820 - $49,109
3,456 Added 10.3%
37,013 $467,000
Q1 2020

May 06, 2020

SELL
$6.8 - $14.66 $6,963 - $15,011
-1,024 Reduced 2.96%
33,557 $307,000
Q4 2019

Feb 05, 2020

BUY
$12.82 - $16.85 $27,575 - $36,244
2,151 Added 6.63%
34,581 $482,000
Q3 2019

Oct 23, 2019

BUY
$16.31 - $28.29 $1,141 - $1,980
70 Added 0.22%
32,430 $558,000
Q2 2019

Aug 14, 2019

BUY
$19.18 - $27.88 $91,411 - $132,876
4,766 Added 17.27%
32,360 $881,000
Q1 2019

May 01, 2019

SELL
$8.0 - $19.66 $3,160 - $7,765
-395 Reduced 1.41%
27,594 $528,000
Q4 2018

Jan 31, 2019

BUY
$8.59 - $18.05 $78,048 - $164,002
9,086 Added 48.07%
27,989 $263,000
Q3 2018

Nov 07, 2018

SELL
$17.11 - $21.74 $23,184 - $29,457
-1,355 Reduced 6.69%
18,903 $358,000
Q2 2018

Aug 06, 2018

BUY
$16.76 - $23.92 $52,492 - $74,917
3,132 Added 18.29%
20,258 $396,000
Q1 2018

May 02, 2018

BUY
$16.16 - $31.31 $40,286 - $78,055
2,493 Added 17.04%
17,126 $322,000
Q4 2017

Feb 09, 2018

SELL
$12.26 - $25.88 $19,591 - $41,356
-1,598 Reduced 9.85%
14,633 $243,000
Q3 2017

Nov 06, 2017

BUY
$8.37 - $20.59 $135,853 - $334,196
16,231
16,231 $334,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $226M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.